TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

Journal of Clinical Investigation

Volumn 103, Issue 2, 1999, Pages 197-206

  Yin, Juan Juan ^a   Selander, Katri ^a   Chirgwin, John M ^a   Dallas, Mark ^a   Grubbs, Barry G ^a   Wieser, Rotraud ^b   Massagué, Joan ^b   Mundy, Gregory R ^a   Guise, Theresa A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PARATHYROID HORMONE RELATED PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HORMONE RELEASE; HUMAN; HUMAN CELL; MOUSE; MUTANT; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 0032918414     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3523     Document Type: Article

References (45)

1. Paget, S. 1889. The distribution of secondary growths in cancer of the breast. Lancet. 1:571-572.
2. Coleman, R.E., and Rubens, R.D. 1987. The clinical course of bone metastases from breast cancer. Br. J. Cancer. 55:61-66.
3. Hauschka, P.V., Mavrakos, A.E., Iafrati, M.D., Doleman, S.E., and Klagsbrun, M. 1986. Growth factors in bone matrix. J. Biol. Chem. 261:12665-12674.
4. Pfeilschifter, J., and Mundy, G.R. 1987. Modulation of transforming growth factor β activity in bone cultures by osteotrophic hormones. Proc. Natl. Acad. Sci. USA. 84:2024-2028.
5. Boyde, A., Maconnachie, E., Reid, S.A., Delling, G., and Mundy, G.R. 1986. Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc. 4:1537-1554.
6. Hortobagyi, G.N., et al. 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. 335:1785-1791.
7. Diel, I.J., et al. 1998. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339:357-363.
8. Burtis, W.J., et al. 1987. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J. Biol. Chem. 262:7151-7156.
9. Moseley, J.M., et al. 1987. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc. Natl. Acad. Sci. USA. 84:5048-5052.
10. Strewler, G.J., et al. 1987. Parathyroid hormone-like protein from human renal carcinoma cells structural and functional homology with parathyroid hormone. J. Clin. Invest. 80:1803-1807.
11. Jüppner, H., et al. 1991. AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 254:1024-1026.
12. Abou-Samra, A., et al. 1992. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc. Natl. Acad. Sci. USA. 89:2732-2736.
13. Burtis, W.J., et al. 1990. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N. Engl. J. Med. 322:1106-1112.
14. Hundred, N.J., et al. 1991. Parathyroid hormone related protein and hypercalcaemia in breast cancer. Br. Med. J. 303:1506-1509.
15. Powell, G.J., et al. 1991. Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res. 51:3059-3061.
16. Southby, J., et al. 1990. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res. 50:7710-7716.
17. Guise, T.A., et al. 1996. Evidence for a causal role of parathyroid hormone-related protein in breast cancer-mediated osteolysis. J. Clin. Invest. 98:1544-1548.
18. Zakalik, D., Diep, D., Hooks, M.A., Nissenson, R.A., and Strewler, G.J. 1992. Transforming growth factor β increases stability of parathyroid hormone-related protein messenger RNA. J. Bone Miner. Res. 7:104A, S118.
19. Kiriyama, T., et al. 1992. Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator? Mol. Cell. Endocrinol. 92:55-62.
20. Merryman, J.I., DeWille, J.W., Werkmeister, J.R., Capen, C.C., and Rosol, T.J. 1994. Effects of transforming growth factor-β on parathyroid hormone-related protein production and ribonucleic acid expression by a squamous carcinoma cell line in vitro. Endocrinology. 134:2424-2430.
21. Southby, J., Murphy, L.M., Martin, T.J., and Gillespie, M.T. 1996. Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone-related protein. Endocrinology. 137:1349-1357.
22. Cailleau, R., Yong, R., Olive, M., and Reeves, W.J. 1974. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661-674.
23. Wieser, R., Attisano, L., Wrana, J.L., and J. Massagué, 1993. Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. Mol. Cell. Biol. 13:7239-7247.
24. Wieser, R., Wrana, J.L., and Massagué, J. 1995. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J. 14:2199-2208.
25. Cárcamo, J., et al. 1994. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol. Cell. Biol. 14:3810-3821.
26. Guise, T.A., Chirgwin, J.M., Favarato, G., Boyce, B.F., and Mundy, G.R. 1992. Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. Lab. Invest. 67:477-485.
27. Pandian, M.R., Morgan, C.H., Carlton, E., and Segre, G.V. 1992. Modified immunoradiometric assay of parathyroid hormone-related protein: clinical application in the differential diagnosis of hypercalcemia. Clin. Chem. 38:282-288.
28. Massagué, J. 1998. TGF-β signal transduction. Annu. Rev. Biochem. 67:753-791.
29. Sasaki, A., et al. 1995. The bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55:3551-3557.
30. Arteaga, C.L., Dugger, T.C., and Hurd, S.D. 1996. The multifunctional role of transforming growth factor (TGF)-βs on mammary epithelial cell biology. Breast Cancer Res. Treat. 38:49-56.
31. Pierce, D.F., Jr., et al. 1995. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci. USA. 92:4254-4258.
32. Sun, L., et al. 1994. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269:26449-26455.
33. Böttinger, E.P., Jakubczak, J.L., Haines, D.C., Bagnall, K., and Wakefield, L.M. 1997. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumori-genesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 57:5564-5569.
34. Markowitz, S., et al. 1995. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1336-1338.
35. Eppert, K., et al. 1996. MADR2 maps to 18q12 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 88:543-552.
36. Zhu, Y., Richardson, J.A., Parada, L.F., and Graff, J.M. 1998. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 94:703-714.
37. Hahn, S.A., et al. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:259-253.
38. Takaku, K., et al. 1998. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Ape genes. Cell. 92:645-656.
39. Cui, W.E., et al. 1996. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 86:531-542.
40. Caulin, C., Scholl, S.G., Frontelo, P., Gamallo, C., and Quintanilla, M. 1995. Chronic exposure of cultured transfected mouse epidermal cells to TGFβ1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ. 6:1027-1035.
41. Miettinen, P.J., Ebner, R., Lopez, A.R., and Derynck, R. 1994. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127:2021-2036.
42. Oft, M., et al. 1996. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10:2462-2477.
43. Kretzschmar, M., Doody, J., and Massagué, J. 1997. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1. Nature. 389:618-622.
44. Sepp-Lorenzino, L., et al. 1995. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:5302-5309.
45. Böttinger, E.P., et al. 1997. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J. 16:2621-2633.